Patience is a virtue for big pharma buyers
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
SITC 2018 – The search for immuno-oncology combos continues
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Esmo 2018 – Without overwhelming efficacy the me-too PD-1 chase is futile
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?
Esmo 2018 – Lynparza delivers a huge result in first-line ovarian cancer
A dramatic extension in progression-free survival in Astrazeneca's Solo-1 study raises the prospect of improving cure rates in ovarian cancer, though the impact…
Esmo 2018 – Encouraging early prostate data fail to lift Clovis
Response rates in BRCA-positive patients hint at Parp inhibitors’ potential in prostate cancer, but Clovis reins in hopes for a different genetic marker.
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Asco 2018 event analyser – A year of reset expectations
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
